A retrolective cohort analysis of therapeutical data of efficacy and safety of an oral enzyme combination compared to nonsteroidal anti-inflammatory drugs in activated degenerative rheumatic disease and in fibromyalgia

Bock P.R.*, Hanisch J.*, Schiess W.**, Stauder G.M.**, Wittenborg A.***

* IFAG, Institute for Medical Research and Statistics, CH-4056 Basel, Switzerland
** Dept. Clinical Research, MUCOS Pharma GmbH & Co., D-82524 Geretsried, Germany
*** Center of Rheumatology Ruhrgebiet, Herne, Germany

2^nd Central European Congress of Rheumatology, 13-16 May, 1998, Warsaw, Poland 
published in Reumatologia 1998, Suppl Vol. XXXVI, Warsaw 1998, Lectures No. 214, pp 114-116  
ISSN 0034-6233

619 KA (19-09-2)

Objective

Proteolytic oral enzymes (OE) (Wobe-Mugos E, MUCOS Pharma GmbH & Co., D-82524 Geretsried, Germany) have been found effective therapeutically in certain states of inflammation such as traumatology, rheumatology, after surgery, in patients with thrombophlebitis, as well as in urologic and gynecologic inflammations with minimal adverse effects associated with their use. Enzyme combination preparations are widely used in these indications and a large amount of data exists with the prescribers of this therapy.
In order to supplement the existing knowledge regarding the clinical efficacy and safety of OE in the treatment of rheumatic diseases with data on more patients the present retrolective cohort analysis of therapeutical data has been conducted. The aim of this study was to compare OE to drugs used as the first line of therapy in such patients - nonsteroidal anti-inflammatory drugs (NSAID) - under the conditions of disease management by the general practitioner.